Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
AGL.L
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q1.22
N/A
-0.02
vs -0.02
Q2.22
N/A
-0.04
vs -0.04
Q3.22
N/A
-0.02
vs -0.02
Q4.22
N/A
-0.05
vs -0.03
Q1.23
N/A
-0.02
vs -0.02
Q2.23
N/A
-0.04
vs -0.04
Q3.23
N/A
-0.02
vs -0.02
Q4.23
N/A
-0.02
vs -0.05
Q1.24
N/A
-0.01
vs -0.02
Q2.24
N/A
-0.01
vs -0.04
Sales Growth
YoY
Current
Estimates
Q2.22
+42%
419K vs 296K
Q3.22
-13%
311K vs 358.5K
Q4.22
-13%
622K vs 717K
Q1.23
+185%
598K vs 209.5K
Q2.23
+185%
1.2M vs 419K
Q3.23
+59%
495K vs 311K
Q4.23
-20%
495K vs 622K
Q1.24
-14%
517K vs 598K
Q2.24
-57%
517K vs 1.2M
Q4.24
+19%
591.2K vs 495K
Return on Equity
QoQ
Q3.22
-16%
-0.16
vs -0.29
Q4.22
-31%
-0.31
vs -0.16
Q1.23
-15%
-0.15
vs -0.31
Q2.23
-31%
-0.31
vs -0.15
Q3.23
-22%
-0.22
vs -0.31
Q4.23
-22%
-0.22
vs -0.22
Q1.24
-16%
-0.16
vs -0.22
Q2.24
-16%
-0.16
vs -0.16
Institutionnal Ownership
Relative Strength
AGL.L
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Quote Panel
Key Metrics
Forecast
499%2025-Revenue
-178%2025-EPS
20%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD multiplex analysis system for routine and focused multiplex analysis of DNA, RNA or protein biomarkers. The company was founded in 1994 and is based in Guildford, the United Kingdom.
LSE
Unprofitable
EPS improving
Unprofitable
EPS improving
-0.25Â ( -3.85%)
Relative Strenght
Volume Buzz
174%
Earning Acce
No
Dist 52w H.
64%Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How AGL.L compares to sector?